Literature DB >> 18199613

1-11C-acetate kinetics of prostate cancer.

Christiaan Schiepers1, Carl K Hoh, Johan Nuyts, Marc Seltzer, Christine Wu, Sung-Cheng Huang, Magnus Dahlbom.   

Abstract

UNLABELLED: (18)F-FDG is in widespread use in cancer imaging but has limited utility in staging and monitoring of prostate cancer. 1-(11)C-Labeled acetate, a substrate for the citric acid cycle, is superior. The kinetics of prostate tumors were investigated.
METHODS: Ten patients with primary prostate cancer, 10 with recurrent tumor, and 2 men with benign prostate hypertrophy were studied. After administration of 5.5 MBq/kg 1-(11)C-acetate, dynamic PET of the pelvis was acquired for 20 min. Images were reconstructed with iterative algorithms, and corrections for attenuation and scatter were applied. Factor analysis produced factor images, representing iliac vessels and the prostate from which blood-input and tissue-output functions were derived with simple thresholding techniques. Five different kinetic models were applied to the dynamic data to estimate the rate constants.
RESULTS: The standard 3-compartment, 2-tissue model was able to describe 1-(11)C-acetate kinetics of the prostate. The model could be reduced to 3 parameters by setting the tissue blood fraction and release from the second tissue compartment (k(4)) to zero. Correction for metabolites appeared to be necessary. This reduced model performed marginally better than a 2-compartment model. A significant correlation was found between the influx rate constant (K) and acetate uptake (standardized uptake value) for primary tumors (r = 0.91), whereas there was no correlation for recurrent tumors (r = -0.17). Patlak graphical analysis provided accurate parameter estimates.
CONCLUSION: A 3-compartment, 3-parameter model is able to describe adequately the acetate kinetics in prostate cancer. Significant differences between primary and recurrent cancer were found for transport k(1), influx K, distribution volume V(d), as well as early (6-10 min) and late (15-20 min) 1-(11)C-acetate uptake.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199613     DOI: 10.2967/jnumed.107.044453

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  27 in total

Review 1.  Beyond haematuria in uro oncology: imaging biomarkers lag behind needs.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01       Impact factor: 9.236

Review 2.  Image-derived input function for brain PET studies: many challenges and few opportunities.

Authors:  Paolo Zanotti-Fregonara; Kewei Chen; Jeih-San Liow; Masahiro Fujita; Robert B Innis
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-03       Impact factor: 6.200

Review 3.  Advances in prostate cancer imaging techniques and strategies.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05       Impact factor: 9.236

Review 4.  Novel Approaches to Imaging Tumor Metabolism.

Authors:  Sui-Seng Tee; Kayvan R Keshari
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

Review 5.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

6.  PET Imaging of Prostate Cancer Using C-Acetate.

Authors:  Johannes Czernin; Matthias R Benz; Martin S Allen-Auerbach
Journal:  PET Clin       Date:  2009-04

7.  Patlak image estimation from dual time-point list-mode PET data.

Authors:  Wentao Zhu; Quanzheng Li; Bing Bai; Peter S Conti; Richard M Leahy
Journal:  IEEE Trans Med Imaging       Date:  2014-04       Impact factor: 10.048

8.  11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation.

Authors:  Esther Mena; Baris Turkbey; Haresh Mani; Stephen Adler; Vladimir A Valera; Marcelino Bernardo; Vijay Shah; Thomas Pohida; Yolanda McKinney; Gideon Kwarteng; Dagane Daar; Maria L Lindenberg; Philip Eclarinal; Revia Wade; W Marston Linehan; Maria J Merino; Peter A Pinto; Peter L Choyke; Karen A Kurdziel
Journal:  J Nucl Med       Date:  2012-02-17       Impact factor: 10.057

Review 9.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

10.  Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer.

Authors:  Jens Sörensen; Rikard Owenius; Michelle Lax; Silvia Johansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.